Allergy Therapeutics (GB:AGY) has released an update.
Maximize Your Portfolio with Data Driven Insights:
- Leverage the power of TipRanks' Smart Score, a data-driven tool to help you uncover top performing stocks and make informed investment decisions.
- Monitor your stock picks and compare them to top Wall Street Analysts' recommendations with Your Smart Portfolio
Allergy Therapeutics has submitted a Marketing Authorisation Application to Germany’s Paul Ehrlich Institut for its innovative Grass MATA MPL allergy treatment. This submission marks a crucial step in the regulatory process for the subcutaneous immunotherapy designed to alleviate symptoms of grass pollen allergies. The application is supported by comprehensive data, including a pivotal Phase III trial showcasing significant efficacy over placebo.
For further insights into GB:AGY stock, check out TipRanks’ Stock Analysis page.
